SK Biofarm to Showcase AI Drug Development Strategies at BIO USA

SK Biofarm is set to participate in the 2026 BIO International Convention (BIO USA) in San Diego, California, from June 22 to 25. This marks the company's second consecutive year with a solo booth at the event, which is organized by the Biotechnology Innovation Organization and expects over 20,000 attendees from more than 76 countries.

The company's booth will be located in the "Digital Health and AI Zone," highlighting its commitment to integrating artificial intelligence into drug development and business operations. SK Biofarm plans to engage in one-on-one partnering meetings with global pharmaceutical companies and investors to discuss potential collaborations in research and development, business development, and novel modalities.

Under the slogan "SK, AI for Every Patient," SK Biofarm will present its AI-based drug discovery pipeline, digital transformation initiatives, and patient-centric platforms. The company is actively enhancing its proprietary AI platform for predictive modeling and data analysis, with plans to expand AI applications across various stages of the drug development process, from research planning to operational optimization.

"We will seek new collaboration opportunities with the global pharmaceutical and biotech industries and introduce our R&D capabilities and AI utilization strategies," said SK Biofarm CEO Lee Dong-hoon. "We will increase the productivity and execution capabilities of drug development using AI and data."

“

We will seek new collaboration opportunities with the global pharmaceutical and biotech industries and introduce our R&D capabilities and AI utilization strategies. We will increase the productivity and execution capabilities of drug development using AI and data.